Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients With Advanced Solid Tumors

NCT06598007 is registered in ClinicalTrials.gov with Crossignal Therapeutics, Inc. as lead sponsor.

NCT NCT06598007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06598007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients With Advanced Solid Tumors
Lead sponsor
Crossignal Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 20, 2024
Completion date
June 30, 2027
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, pancreatic ductal adenocarcinoma, solid tumor, adult